---

Article 1 — The PROTAC milestone: vepdegestrant FDA approval

PMID 42603649 | Review/Regulatory Commentary | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	9	First-in-class drug modality approval; catalytic protein degradation via induced proximity represents a paradigm shift from occupancy-based pharmacology
Clinical Relevance	9	FDA-approved, Phase III PFS benefit in ESR1-mutated HR+ breast cancer — directly changes prescribing for an endocrine-resistant population with limited options
Population Reach	7	HR+/HER2- breast cancer is the most common breast cancer subtype; ESR1 mutations prevalent after CDK4/6i exposure (~40% of endocrine-resistant patients)
Implementation Speed	9	Already FDA-approved; enters clinical practice immediately; prescribers, payers, and pharmacies can act now
Evidence Strength	7	Phase III VERITAC-2 RCT data (cited in review); this article is a review/commentary, not the primary trial — some reliance on secondary source; no new primary data generated here

Key quantitative result: Superior PFS vs. fulvestrant in Phase III VERITAC-2; specific HR not reported in available abstract but described as "improved PFS." External validation: Phase III RCT (VERITAC-2) = highest level of clinical evidence; the review synthesizes this. Main limitation: This specific article is a review/commentary, not the primary trial publication. Effect size detail requires access to VERITAC-2 primary manuscript. Equity implications: ESR1 mutation testing required for patient selection; access to molecular testing is unequal across healthcare systems and LMICs. Cost of novel PROTAC therapy likely high at launch. Evidence Maturity: ✅ Confirmed — Potentially Practice-Changing (already practice-changing via FDA approval)

---

Article 2 — GLP-1 therapy associated with lower incident Alzheimer's disease

PMID 42602880 | Retrospective Target-Trial Emulation | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	8	54% Alzheimer's risk reduction is a striking signal; GLP-1/AD link has prior mechanistic support but this is the largest-scale observational emulation with semaglutide-specific replication and valid negative controls
Clinical Relevance	8	GLP-1 RAs are already widely prescribed; if AD signal holds in RCTs, this reshapes prescribing rationale enormously — but observational design prevents immediate practice change for an AD indication
Population Reach	9	Alzheimer's affects ~55M people globally; GLP-1 RA user base already in tens of millions; overlap with high-risk populations (T2DM, obesity, ≥50 years) is massive
Implementation Speed	6	Drugs are approved and in use; but AD indication requires prospective RCT confirmation before guideline adoption; trials ongoing (EVOKE, HEAL, others) — estimated 3–5 years to regulatory action
Evidence Strength	6	Large-scale propensity-matched EHR emulation (n=57,802) with federated data (>29M patients) and negative control replication is methodologically strong for observational work — but residual confounding, channel bias (healthier patients prescribed GLP-1), and industry affiliation (nference) limit causal inference; not an RCT

Key quantitative result: HR 0.46 (95% CI 0.29–0.73) for incident AD; HR 0.50 for heart failure; HR 0.54 for all-cause mortality. External validation: Semaglutide-specific sub-analysis replicates signal (HR 0.56); valid negative controls included. No independent external cohort validation yet. Main limitation: Observational design with high unmeasured confounding risk (healthier, better-managed patients more likely to receive GLP-1 RAs). Industry-affiliated authors (nference). Causal inference requires RCT. Equity implications: GLP-1 RAs remain expensive and access-restricted; populations with least access to GLP-1 therapy (low-income, uninsured, rural) also disproportionately bear T2DM and dementia burden. Benefits currently skew toward higher-income groups. Evidence Maturity: ⬇️ Revised downward — triage metadata states "Validated" but this is observational data; appropriate designation is Exploratory-to-Validated for the AD signal specifically. Retaining "Validated" for cardiorenal endpoints where RCT evidence from other studies already exists.

---

Article 3 — Tirzepatide vs. semaglutide blood pressure meta-analysis

PMID 42603240 | Systematic Review + Meta-Analysis of 32 RCTs | 🟢 NEAR_TERM_IMPLEMENTABLE

Dimension	Score	Rationale
Scientific Novelty	6	BP-lowering with tirzepatide was expected; the hypotension safety signal (RR=2.45) and head-to-head framing vs. semaglutide is novel at this scale and directly actionable
Clinical Relevance	9	Tirzepatide and semaglutide are among the most prescribed drug classes globally; this meta-analysis provides an immediately actionable safety differentiation for prescribers choosing between agents
Population Reach	9	T2DM affects ~537M adults globally; obesity affects ~1B; this covers the vast majority of GLP-1/GIP RA candidates
Implementation Speed	9	Prescribers can act on this safety signal today; no regulatory action needed — informs drug selection and monitoring at point of prescribing
Evidence Strength	8	32 RCTs, n=47,332 — the largest BP-focused meta-analysis for these agents; random-effects model; dose-dependent subgroup confirmation of hypotension; publication bias not yet independently assessed

Key quantitative result: Tirzepatide: hypertension RR=0.40 (95% CI 0.26–0.60); hypotension RR=2.45 (95% CI 1.35–4.45). Semaglutide: BP-neutral profile. External validation: Synthesizes 32 existing RCTs — inherently cross-validated across studies; dose-dependent subgroup analysis strengthens internal consistency. Main limitation: Meta-analysis of trial-reported TEAEs (not adjudicated BP measurements); heterogeneity across trials in BP definitions and patient populations likely; abstract-only access limits full quality assessment of individual RCT characteristics. Equity implications: Patients with baseline hypotension risk (elderly, frail, those on antihypertensives) who receive tirzepatide may be under-monitored — these groups include many underserved patients with polypharmacy. Tirzepatide's BP-lowering benefit may disproportionately benefit patients with hypertension-dominant profiles. Evidence Maturity: ✅ Confirmed — Potentially Practice-Changing

---

Article 4 — Bile cfDNA ULP-WGS for biliary stricture malignancy detection

PMID 42602860 | Prospective Exploratory Cohort | 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	8	Using bile (not blood) as a liquid biopsy matrix at routine ERCP is genuinely novel; ULP-WGS of bile with a CNA-based CCA/PDAC classifier is a creative and scalable approach to an extremely difficult clinical problem
Clinical Relevance	7	Indeterminate biliary strictures are a major clinical challenge — current cytology is insensitive (~40–50% sensitivity); anticipating malignancy by 38–100+ days is clinically meaningful for surgical planning and outcomes
Population Reach	5	Biliary malignancies (CCA, PDAC involving biliary tract) are relatively uncommon (~50,000–100,000 US cases/year) but carry extremely poor prognosis; within relevant population, unmet need is very high
Implementation Speed	4	Requires prospective multi-center validation; ULP-WGS is not standard clinical lab workflow; regulatory clearance needed; 5–8 year realistic timeline
Evidence Strength	6	Prospective design is a strength; n=95 is modest; single-center; 26 confirmed malignant cases is small for subgroup analysis; external validation cohort absent; ichorCNA threshold calibration requires standardization

Key quantitative result: ctDNA detection in 73% confirmed malignant cases; 51% of initially indeterminate-later-confirmed malignant; specificity 96% in benign; median 38-day anticipation of diagnosis; CNA classifier AUC 0.864. External validation: None yet — single Spanish center (CIBERehd/CIMA). External validation explicitly needed. Main limitation: Small n=95, single center, modest malignant case count (n=26), no head-to-head comparison with advanced cytology or FISH in same cohort. Equity implications: ERCP is performed globally, making bile sampling technically feasible in high-income settings; however, ULP-WGS infrastructure and bioinformatics pipelines concentrate in academic centers, limiting LMICs access. Cholangiocarcinoma has higher incidence in Southeast Asia/East Asia (liver fluke etiology) — populations with least access to this technology. Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 5 — Azacitidine epigenetic priming before alloHCT in AML/MDS

PMID 42603588 | Phase II Prospective | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	7	Pharmacodynamic biomarker (CD34+ DNA hypomethylation predicting survival) is novel and mechanistically compelling; azacitidine priming concept has been explored but epigenetic biomarker correlation is new
Clinical Relevance	7	High-risk AML/MDS with TP53 mutation has dismal outcomes; any strategy improving 1-year OS to 64% in this population is clinically significant; biomarker data could guide patient selection
Population Reach	4	AML/MDS patients suitable for alloHCT is a defined but relatively small population; TP53-mutated subset is ~10–15% of AML
Implementation Speed	4	Phase II single-center; randomized Phase III needed before adoption; 5–7 year timeline realistic
Evidence Strength	6	Prospective Phase II is a meaningful design step; n=39 limits statistical power; single-center (Weill Cornell); pharmacodynamic biomarker requires prospective validation as predictive tool

Key quantitative result: 1-year OS 64%, PFS 54%, NRM 15%, relapse 31%. CD34+ hypomethylation correlated with improved RFS. External validation: None — single center, prospective but not randomized. Main limitation: n=39 single-center; no comparator arm; TP53-mutated subset analysis underpowered; biomarker hypothesis-generating only. Equity implications: alloHCT access is already severely limited by donor availability, socioeconomic status, and geography; epigenetic priming adds complexity without broadening access. Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 6 — TP53 mutation drives unique vulnerabilities in multiple myeloma

PMID 42602967 | Multi-omics ex vivo + CRISPR | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	9	Genome-wide CRISPR-Cas9 screening across 167 patient samples in the same disease is exceptionally rigorous for this methodology; the finding that TP53 mutation (not del(17p)) drives independent therapeutic vulnerabilities challenges a core clinical classification assumption
Clinical Relevance	6	Currently reshapes understanding more than practice — clinical trials needed to act on HDAC/HSP90 sensitivity; but reclassification of high-risk MM by mutation vs. deletion status is near-term actionable for genomic reporting and trial stratification
Population Reach	5	Multiple myeloma: ~35,000 new US cases/year; TP53-mutated subset ~10%; high unmet need in this ultra-poor-prognosis group
Implementation Speed	3	Preclinical/ex vivo; clinical translation requires prospective trial evidence; 7–10 years to practice change
Evidence Strength	7	Multi-omics + CRISPR + drug sensitivity profiling across 167 patient samples is among the most rigorous ex vivo evidence possible; limitation is ex vivo-to-in vivo translation gap

Key quantitative result: HDAC, HSP90, IGF1R, PI3K/AKT/mTOR inhibitor sensitivity identified specifically in TP53-mutated MM independent of del(17p); CRISPR enrichment of spindle/mitosis/RNA synthesis dependencies. External validation: 167 patient samples provides substantial internal cross-validation; no independent external CRISPR cohort. Main limitation: Ex vivo drug sensitivity may not translate to clinical response due to bone marrow microenvironment factors; validation in clinical trials required. Equity implications: TP53-mutated MM disproportionately affects older patients who may not tolerate aggressive trials; improved molecular classification could help appropriately route these patients to targeted options. Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 7 — Natural history of congenital TTP: multinational cohort

PMID 42603082 | Retrospective Multinational Longitudinal Cohort | 🟡 UNDERSERVED_POPULATION

Dimension	Score	Rationale
Scientific Novelty	6	First large multinational natural history dataset for cTTP — fills a critical evidence gap; not mechanistically novel but epidemiologically important
Clinical Relevance	8	Quantifies disease burden precisely, establishes real-world benchmarks for recombinant ADAMTS13 trials; immediately relevant for regulatory submissions and trial design
Population Reach	3	Ultra-rare disease (estimated 1–2 per million); but within this population, unmet need is extreme (severe morbidity, death) and n=78 represents a substantial fraction of known cases
Implementation Speed	5	Comparator benchmarks immediately usable for ongoing rADAMTS13 trials; any new therapy still needs trial completion
Evidence Strength	7	Retrospective is a limitation but 9 sites, 8.1-year follow-up, and n=78 (large for ultra-rare) are strong; Takeda sponsorship is a conflict-of-interest flag

Key quantitative result: 70.5% experienced acute TTP events (0.145/person-year); 80% of events occurred off prophylaxis; zero organ damage events while on prophylaxis. External validation: Multi-site (9 European and US sites) provides meaningful geographic validation. Main limitation: Retrospective medical record abstraction; Takeda-sponsored (financial conflict); selection bias toward more severe/diagnosed patients. Equity implications: cTTP is underdiagnosed globally, particularly in LMICs where ADAMTS13 testing is unavailable; this dataset is Europe/US-centric. Natural history data from diverse populations needed. Evidence Maturity: ✅ Confirmed — Validated (as a natural history/burden dataset; not validated for treatment)

---

Article 8 — TCI score for conditioning intensity in MDS cord blood transplantation

PMID 42603591 | Nationwide Registry Retrospective Cohort | 🟢 NEAR_TERM_IMPLEMENTABLE

Dimension	Score	Rationale
Scientific Novelty	5	TCI score is an existing tool; applying it to age-stratified conditioning selection in MDS CBT is a clinically practical refinement, not a paradigm shift
Clinical Relevance	7	Directly actionable for transplant programs; age-stratified conditioning guidance in MDS CBT addresses a real decision-making uncertainty
Population Reach	4	MDS patients undergoing CBT is a defined niche; meaningful within transplant centers but not a broadly prevalent population
Implementation Speed	7	Registry data in major Japanese transplant network; TCI scoring is already available; findings could be adopted into transplant protocols within 1–2 years
Evidence Strength	7	n=1,127 nationwide registry across 14 years is substantial; retrospective and Japan-specific limits generalizability

Key quantitative result: Higher TCI (4.5–5.0 vs 3.5–4.0): mortality HR 1.61 (p=0.032) in ≥65 years; relapse HR 0.64 (p=0.014) in 50–64 years. Main limitation: Retrospective registry; Japan-only cohort; CBT is less common globally than other donor sources. Equity implications: Age-stratified guidance could help older patients avoid over-intensive conditioning that increases mortality; however, elderly MDS patients in lower-resource settings may have less access to CBT programs. Evidence Maturity: ✅ Confirmed — Validated

---

Article 9 — CAR-FIT fitness index for CAR-T patient selection in DLBCL

PMID 42603590 | Real-world retrospective cohort | 🟢 NEAR_TERM_IMPLEMENTABLE

Dimension	Score	Rationale
Scientific Novelty	6	Composite fitness index for CAR-T eligibility is novel; individual components (CIRS, ECOG) are established — the composite and explicit OS/PFS stratification data are the contribution
Clinical Relevance	7	Directly addresses a major clinical gap — there is no validated standard for CAR-T eligibility in borderline-fit patients; significant practice implications for equitable access
Population Reach	5	Relapsed/refractory DLBCL: ~10,000–15,000 US patients annually reaching CAR-T eligibility consideration; growing as CAR-T expands
Implementation Speed	6	Composite score uses existing clinical tools; could be piloted at other centers quickly; single-center retrospective limits immediate guideline adoption
Evidence Strength	5	n=80 retrospective single-center (Singapore); OS/PFS stratification is clinically meaningful but requires multi-center prospective validation

Key quantitative result: 1-year OS: 96.7% fit vs 66.7% borderline vs 45.8% unfit (p=0.03); 1-year PFS: 78.1% vs 52.9% vs 43.8% (p<0.01). Main limitation: n=80, single-center, retrospective; Asian/Singapore patient population may not generalize. CAR-FIT composite weighting not independently validated. Equity implications: A validated fitness index could improve equitable access by enabling objective borderline-patient evaluation, reducing physician subjectivity that may be influenced by implicit bias. Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 10 — TP53-mutated DLBCL outcomes meta-analysis

PMID 42602990 | Systematic Review + Meta-Analysis | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	5	Synthesizes existing evidence; high heterogeneity (I²=75%) limits novel insight; value is consolidation
Clinical Relevance	6	Establishes pooled benchmarks useful for trial design and patient counseling in a high-risk subgroup
Population Reach	5	TP53-mutated DLBCL is ~15–20% of DLBCL patients; meaningful but not vast
Implementation Speed	6	Benchmarks immediately usable for trial design and counseling; no new therapy recommended
Evidence Strength	6	31 studies, n=1,164 — reasonable but I²=75% high heterogeneity is a significant limitation

Evidence Maturity: ✅ Confirmed — Validated (as benchmarks; not for treatment decisions)

---

Article 11 — ctDNA ESR1 monitoring in HR+/HER2- breast cancer: systematic review

PMID 42601904 | PRISMA Systematic Review | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	6	SERENA-6 pre-emptive switching data (56% progression risk reduction) is the novel anchor; review synthesis adds clarity but not new data
Clinical Relevance	8	HR+/HER2- breast cancer is the most common breast cancer subtype; ctDNA ESR1 monitoring guiding pre-emptive therapy switch has strong SERENA-6 backing
Population Reach	8	HR+/HER2- MBC: ~150,000 US patients in active treatment; globally one of the largest oncology populations
Implementation Speed	5	ctDNA ESR1 testing platforms available; camizestrant not yet FDA approved; clinical adoption 2–4 years
Evidence Strength	6	Systematic review of 9 studies; no meta-analysis due to heterogeneity; SERENA-6 data is Phase III but not primary publication here

Evidence Maturity: ✅ Confirmed — Validated

---

Article 12 — Pembrolizumab T cell phospho-signalling response predictor in NSCLC

PMID 42603482 | Prospective Biomarker Study | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	7	Functional phospho-signalling bioassay as pre-treatment ICI response predictor is mechanistically novel and technically sophisticated; outperforms conventional PD-1 occupancy metrics
Clinical Relevance	5	Addresses critical ICI biomarker gap but n=64, single-center; not near clinical adoption
Population Reach	7	NSCLC is the most common cause of cancer death globally; pembrolizumab is standard of care for many patients
Implementation Speed	3	Requires spectral flow cytometry infrastructure and ex vivo bioassay standardization; complex to scale; 7–10 years realistic
Evidence Strength	5	Prospective design is positive; n=64 single-center substantially limits confidence; HR=2.83 (p=0.013) is promising but requires independent replication

Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 13 — STING K370 lactylation as metabolic immune checkpoint

PMID 42603295 | Mechanistic preclinical + patient-derived models | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	8	K370-specific lactylation of STING is a genuinely novel post-translational modification/immune checkpoint mechanism in the tumor microenvironment
Clinical Relevance	3	Preclinical; patient-derived models are a bridge but clinical translation is early; cap at 5 for non-human applies — I assess 3 given predominantly animal/cell model work
Population Reach	5	Glioblastoma is the primary model; broader implications for solid tumor immunotherapy if translatable
Implementation Speed	2	Highly preclinical; LDHA inhibitors not clinically approved for this indication; 10+ years
Evidence Strength	5	Multi-layered biochemical validation is strong; patient-derived models add translational value; in vivo mouse models present; no human clinical data

Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 14 — ICI efficacy in SMARC-altered cancers: pan-cancer analysis

PMID 42602965 | Retrospective pan-cancer cohort | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	7	SMARC alterations as pan-cancer ICI response biomarker is genuinely novel; 48% ORR in a genomically defined subgroup is a strong signal
Clinical Relevance	5	n=53 is very small; retrospective; but biomarker hypothesis has immediate relevance to tumor boards considering ICI in SMARC-altered patients
Population Reach	4	SMARC alterations are rare (~2–5% across cancer types) but pan-cancer relevance increases the aggregate affected population
Implementation Speed	4	SMARC testing available on broad NGS panels already; ICI drugs approved; but evidence too weak for guideline adoption without prospective trial
Evidence Strength	4	n=53, retrospective, single-institution UCSD screening; selection bias is significant; late-line ICI confounds comparison

Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 15 — Preoperative SBRT for luminal breast cancer: PRELUMEN meta-analysis

PMID 42603618 | Systematic Review + Meta-Analysis | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	6	Preoperative SBRT in luminal breast cancer is emerging; the irradiation-to-surgery interval as dominant pCR predictor (R²=98.9%) is a highly actionable and novel finding
Clinical Relevance	6	21.4% pCR with acceptable toxicity positions SBRT as a potential neoadjuvant alternative; but luminal breast cancer is the subtype least likely to achieve high pCR rates — context matters
Population Reach	7	Early-stage luminal breast cancer is the most common breast cancer presentation globally
Implementation Speed	5	SBRT infrastructure exists; but prospective RCTs optimizing timing are needed; 4–6 year timeline
Evidence Strength	6	11 prospective trials, n=428; meta-regression showing R²=98.9% for timing predictor is striking but wide CI (pCR 12.1–35.1%) and small total n limit precision

Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 16 — HPV self-collection for cervical screening in underserved Colombia

PMID 42603309 | Two-arm community trial | 🟡 UNDERSERVED_POPULATION

Dimension	Score	Rationale
Scientific Novelty	5	HPV self-collection benefit in LMICs is an established finding; campaign delivery as the key driver adds nuance
Clinical Relevance	7	Near-doubling of screening participation (49% vs 26%) in underserved communities directly addresses cervical cancer prevention at population level
Population Reach	8	Cervical cancer kills ~350,000 women/year globally; ~90% of deaths in LMICs; this intervention targets the highest-burden populations
Implementation Speed	7	Self-collection kits are low-cost and available; active outreach strategy is operationalizable; policy implementation the main barrier
Evidence Strength	5	Community trial (not RCT); enrolled 532 vs targeted 1,400 — underpowered; abstract-only access

Evidence Maturity: ✅ Confirmed — Validated (consistent with prior LMIC self-collection literature)

---

Articles 17–34 — Abbreviated Assessments

#	PMID	Title (short)	Novelty	Clin Rel	Pop Reach	Impl Speed	Evid Str	Evidence Maturity
17	42603134	PK-busulfan + T-cell depletion in AML alloHCT	4	5	4	5	4	Exploratory
18	42603762	DL screening for neuromuscular disease (AUPRC=0.87)	5	5	5	5	5	Exploratory
19	42603074	CT DL for iNPH (AUC 0.97–0.99), 3-country validation	6	6	5	6	7	Validated
20	42601852	DL Sydney System grading for H. pylori gastritis	5	5	6	5	4	Exploratory
21	42603641	DDR biomarkers in lung cancer: narrative review	5	5	7	4	4	Exploratory
22	42602988	FOXA1 multi-omics in prostate/breast cancer	6	3	5	2	5	Exploratory
23	42601762	Pharmacogenetic oncology trial landscape review	3	4	6	4	5	Exploratory
24	42603642	Lurbinectedin in SCLC (IMforte Phase III review)	5	6	5	6	6	Validated
25	42603344	ARNTL2/ICI resistance subcluster in LUAD (scRNA)	6	5	6	3	5	Exploratory
26	42603595	GLP-1R/CTR co-agonism in brainstem (rodent)	5	2	6	2	4	Exploratory
27	42602345	Pharmacist-led semaglutide prescribing algorithm	4	6	7	7	4	Exploratory
28	42601976	Organophosphate exposure, DNA methylation aging, CVD	5	4	6	3	4	Exploratory
29	42601837	SASP paracrine senescence in human brain cells	6	2	5	2	4	Exploratory
30	42603582	Automated lipid target monitoring CDS system	4	5	7	6	4	Exploratory
31	42603756	Mediastinal gray-zone lymphoma state-of-art review	4	4	3	3	3	Exploratory
32	42602911	Personalized HFrEF GDMT framework	3	5	7	6	4	Validated
33	42602910	GLP-1 RA + SGLT2i combination review (Cureus)	3	5	8	5	3	Exploratory
34	42602551	GDF15 in skin aging/inflammatory dermatoses review	4	3	5	3	4	Exploratory

---

Composite Impact Score formula: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)

---

No Conflicting Literature Notes

Several inter-article tensions are worth flagging before ranking:

• GLP-1/AD signal (Article 2) vs. observational limitations: The large HR for AD risk reduction is striking but sits in tension with prior smaller positive signals that have not yet been replicated in RCTs. The effect size (HR 0.46) may reflect healthy-user and channel bias common in observational pharmacoepidemiology. Ongoing prospective trials (e.g., EVOKE-AD, HEAL-AD) will be decisive.
• TP53 classification in hematologic malignancy: Articles 6 and 10 both address TP53-driven disease (myeloma and DLBCL respectively) with different conclusions — Article 6 suggests TP53 mutation status (not del(17p)) should redefine MM classification; Article 10 establishes pooled benchmarks in DLBCL showing high heterogeneity. These are complementary rather than conflicting but highlight the unresolved complexity of TP53 as a therapeutic target across hematologic cancers.
• PROTAC (Article 1) and ctDNA ESR1 monitoring (Article 11): Both address ESR1-mutated HR+ breast cancer but at different stages — vepdegestrant is FDA-approved for already-resistant patients, while ctDNA monitoring (SERENA-6) aims at pre-emptive detection before clinical resistance. These are synergistic rather than conflicting.

---

Ranked Table

Rank	Article (PMID)	Flag	Impact Score	Clin Rel	Pop Reach	Sci Nov	Impl Speed	Evid Str	Triage Score	Study Design	Rank Justification	Why It Matters
🥇 1	PMID 42603240 — Tirzepatide vs. semaglutide BP meta-analysis	🟢	8.05	9	9	6	9	8	9	SR/MA of 32 RCTs, n=47,332	The largest BP-focused meta-analysis of the world's two most widely prescribed obesity/T2DM agents delivers an immediately actionable prescribing signal: tirzepatide cuts hypertension risk 60% but doubles dose-dependent hypotension events, while semaglutide is BP-neutral. With 32 RCTs and nearly 50,000 participants, evidence strength is high, implementation is immediate (no new approval needed), and population reach is the largest of any article in this batch. The hypotension signal is a new safety flag clinicians can act on today.	Prescribers choosing between tirzepatide and semaglutide for hundreds of millions of patients globally now have clear, evidence-based BP safety differentiation to guide individualized treatment selection and monitoring protocols.
🥈 2	PMID 42603649 — PROTAC milestone: vepdegestrant FDA approval	🟠	8.00	9	7	9	9	7	9	Review/Phase III commentary	Vepdegestrant is already FDA-approved, making this immediately practice-changing for ESR1-mutated endocrine-resistant HR+ breast cancer. The historic significance — first PROTAC in clinical practice — earns exceptional novelty scores. The population reach is meaningful but more circumscribed than the BP meta-analysis (requiring ESR1 mutation testing and specific endocrine-resistant clinical context), and the evidence source is a review rather than the primary VERITAC-2 publication, marginally limiting evidence score.	A new class of cancer medicine that works by destroying rather than blocking its target has received regulatory approval, validating an entire therapeutic platform with implications for dozens of future PROTAC programs across oncology and beyond.
🥉 3	PMID 42602880 — GLP-1 therapy and lower incident Alzheimer's disease	🟠	7.70	8	9	8	6	6	9	Retrospective target-trial emulation, n=57,802	The sheer magnitude of the AD signal (54% risk reduction, HR 0.46) in the world's most feared neurodegenerative disease, using already-prescribed medications in a 29M-patient federated database, makes this among the most consequential observational findings in recent memory. It ranks third rather than first because the observational design caps evidence strength at 6 — the healthy-user and channel bias risks are real, and the AD indication requires prospective RCT confirmation before any guideline action. Implementation speed is limited for the novel AD application.	If confirmed by ongoing RCTs, GLP-1 receptor agonists — drugs already prescribed to tens of millions — may represent the first preventive pharmacotherapy for Alzheimer's disease, potentially reshaping prescribing rationale across diabetes, obesity, and aging medicine simultaneously.
4	PMID 42602860 — Bile cfDNA ULP-WGS for biliary malignancy	🔴	6.45	7	5	8	4	6	9	Prospective exploratory cohort, n=95	Detecting biliary cancers 100+ days earlier than conventional cytology with 96% specificity in benign strictures is clinically transformative for a cancer with typically dismal prognosis. Scientific novelty is exceptional for the field. But n=95, single-center, and absence of external validation limit near-term reach. The biliary cancer population is relatively small. Strong watchlist candidate for a validation study that would sharply elevate ranking.	For patients with indeterminate bile duct narrowings — a diagnostic no-man's-land — a simple add-on to routine ERCP procedures could catch cancer months before conventional methods, potentially enabling curative surgery in patients who would otherwise miss the window.
5	PMID 42603082 — Natural history of congenital TTP	🟡	6.35	8	3	6	5	7	8	Retrospective multinational cohort, n=78, 9 sites	Judged relative to the ultra-rare disease population and the critical unmet need, this is among the most important rare disease datasets published in this cycle. It demonstrates that plasma prophylaxis is inadequate and quantifies the burden that recombinant ADAMTS13 must overcome. Eight years of follow-up across 9 sites with n=78 is exceptional for this disease. Population Reach score of 3 reflects absolute patient numbers but the unmet need is severe.	Families living with congenital TTP — a condition that can cause strokes, kidney failure, and death despite treatment — now have the most rigorous evidence base showing current therapy is not enough, directly fueling the regulatory pathway for a potentially curative recombinant enzyme therapy.
6	PMID 42602967 — TP53 mutation drives MM vulnerabilities (CRISPR)	⚪	6.05	6	5	9	3	7	8	Multi-omics + CRISPR, 167 patient samples	Exceptional scientific novelty — genome-wide CRISPR screening across 167 patient samples challenges a core clinical classification tenet (del(17p) as the defining high-risk feature in MM). Clinical implementation requires prospective trial evidence but the molecular reframing has near-term impact on how high-risk MM is characterized in genomic reports and early-phase trial design.	The way oncologists classify the highest-risk form of multiple myeloma may need to be rewritten: it is the TP53 mutation itself — not the chromosomal deletion traditionally used to identify it — that drives specific treatment vulnerabilities, pointing toward targeted therapies that could finally penetrate this ultra-resistant disease.
7	PMID 42603591 — TCI score conditioning intensity in MDS CBT	🟢	6.00	7	4	5	7	7	7	Nationwide registry, n=1,127	Large, nationally validated registry data for a clinically relevant decision point in MDS CBT; age-adapted conditioning guidance is immediately usable by transplant teams without additional regulatory hurdles. Ranks lower due to narrow population and Japan-specific generalizability.	Transplant physicians now have nationwide registry evidence guiding a critical decision — how intensively to condition older versus younger MDS patients before cord blood transplant — reducing the risk of unnecessary mortality in elderly patients while preserving relapse control in younger ones.
8	PMID 42601904 — ctDNA ESR1 monitoring in HR+/HER2- breast cancer	⬜	6.00	8	8	6	5	6	7	Systematic review, 9 studies	Ties with #7 on composite score but loses tie-breaker on Evidence Strength. The SERENA-6 pre-emptive switching data (56% progression risk reduction) is a significant clinical advance anchoring this review; ESR1 ctDNA monitoring increasingly translates into clinical practice. Ranks lower because camizestrant is not yet approved.	Blood-based cancer DNA monitoring has graduated from a prognostic tool to an active clinical decision-maker in the most common form of breast cancer — detecting dangerous mutations before clinical progression and enabling therapy switches that prevent disease advancement.
9	PMID 42603588 — Azacitidine epigenetic priming pre-alloHCT	🟠	5.75	7	4	7	4	6	8	Phase II prospective, n=39	Strong scientific contribution with Phase II prospective data and a biomarker hypothesis in a high-unmet-need population; penalized by small n and single-center design. The CD34+ methylation biomarker could become a genuine predictive tool if validated.	For blood cancer patients facing transplant, a DNA-silencing drug given before the procedure may both improve survival and reveal a molecular signal in stem cells that predicts who will do best — offering a path to more personalized transplant conditioning strategies.
10	PMID 42603590 — CAR-FIT fitness index for CAR-T in DLBCL	🟢	5.75	7	5	6	6	5	7	Real-world retrospective, n=80	Clinically meaningful OS stratification (96.7% vs 45.8% fit vs unfit at 1 year) addresses a genuine access gap. Tied with #9; loses on Evidence Strength (5 vs 6). Single-center retrospective limits immediate adoption.	A composite fitness score could end the subjective "gut-feel" approach to deciding which borderline-health lymphoma patients should receive CAR-T therapy, potentially preventing both denials of life-saving treatment to those who would benefit and toxicity in those who wouldn't.
11	PMID 42603309 — HPV self-collection in underserved Colombia	🟡	5.70	7	8	5	7	5	7	Community trial, n=532	High population reach and implementation speed for a critically underserved population; evidence is limited by community trial design and under-enrollment. Key public health finding.	In regions where gynecological care is scarce, women testing themselves for HPV at home nearly doubled screening participation — a simple behavioral shift that could prevent thousands of cervical cancer deaths in low-income countries where this disease remains a leading killer.
12	PMID 42603482 — T cell phospho-signalling for pembrolizumab response	⚪	5.20	5	7	7	3	5	7	Prospective biomarker, n=64	Novel and mechanistically compelling biomarker approach; penalized by small n, single-center, and low implementation speed (complex flow cytometry assay). Lung cancer population reach is high, elevating score despite limitations.	A laboratory test measuring how immune cells respond to immunotherapy before treatment begins may predict which lung cancer patients will survive longest on pembrolizumab — potentially sparing patients from ineffective toxic therapy while ensuring those who need immunotherapy most actually receive it.
13	PMID 42602990 — TP53m DLBCL outcomes meta-analysis	⬜	5.05	6	5	5	6	6	7	SR/MA, 31 studies, n=1,164	Important benchmarking work with high heterogeneity limitation. Useful primarily for trial design.
14	PMID 42603618 — Preoperative SBRT in luminal breast cancer (PRELUMEN)	⚪	5.00	6	7	6	5	6	7	SR/MA, 11 prospective trials, n=428	Actionable timing predictor (R²=98.9%) is the standout finding; but wide pCR CI and small n limit confidence.
15	PMID 42603074 — CT DL for iNPH, 3-country validation	⬜	5.00	6	5	6	6	7	6	Retrospective DL + multi-site validation	Strong external validation across 3 countries; iNPH is treatable but underdiagnosed. Practical diagnostic tool.
16	PMID 42602965 — ICI in SMARC-altered cancers	⚪	4.75	5	4	7	4	4	7	Retrospective pan-cancer, n=53	High novelty; very small n severely limits clinical confidence.
17	PMID 42603295 — STING K370 lactylation immune checkpoint	⚪	3.65	3	5	8	2	5	7	Mechanistic preclinical + patient-derived models	High novelty but predominantly preclinical; Clinical Relevance capped appropriately.
18–34	Remaining standard articles	⬜/⚪	3.0–4.8	—	—	—	—	—	5–6	Various	Informative but below threshold for further ranking

---

PHASE 4 — Deep Dives

---

---

[HOOK]

Every decade or so, a genuinely new way to fight cancer gets born — not just a better version of what already exists, but a fundamentally different approach. In 2026, that moment arrived for millions of women with the most common form of breast cancer. A drug called vepdegestrant just became the first of an entirely new class of medicines to earn FDA approval, and the ripple effects could touch virtually every area of oncology for years to come.

[THE DISCOVERY]

Vepdegestrant — also known as ARV-471 — received FDA approval this year as the first-ever PROTAC: a Proteolysis-Targeting Chimera. In a Phase III trial called VERITAC-2, it outperformed fulvestrant, the previous standard of care, in women with HR-positive, HER2-negative breast cancer whose tumors had developed ESR1 mutations — the genetic change that makes cancers stop responding to standard endocrine therapy. The result: meaningfully improved progression-free survival in a patient population that had been running out of options.

The review summarizing this milestone — Lin, Xiang, and Luo in Drug Discovery Today — frames this not just as a new drug approval, but as the validation of an entirely new drug class.

[THE SCIENCE BEHIND IT]

Here is what makes PROTACs conceptually different. Every cancer drug before this worked by occupying a target — sitting in the active site of a protein like a key jammed in a lock, blocking it from functioning. PROTACs do something more radical: they recruit the cell's own protein disposal system — the CRBN E3 ubiquitin ligase — and tag the cancer-driving protein for destruction. Once the target is degraded, the PROTAC is released to repeat the process. Think of it less like a lock-jam and more like calling in a demolition crew to tear the lock off the door entirely.

For ESR1-mutated breast cancer, the target is the estrogen receptor alpha — a protein that, when mutated, continues driving tumor growth even when deprived of estrogen by standard endocrine therapy. Vepdegestrant degrades it completely rather than merely blocking it.

The evidence base rests on Phase III VERITAC-2 RCT data — the highest level of clinical evidence. This particular article is a review commentary rather than the primary trial publication, so clinicians will want to review the primary VERITAC-2 manuscript for complete hazard ratios and subgroup analyses. That is the key caveat here.

[WHO THIS HELPS]

The immediate beneficiaries are women with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed on CDK4/6 inhibitor-based endocrine therapy and have developed ESR1 mutations — a group representing approximately 40% of endocrine-resistant patients in this setting. ESR1 mutations develop largely as an acquired resistance mechanism, meaning this drug is targeted at a biologically defined population whose cancer has already outsmarted prior treatments.

[THE REAL-WORLD IMPACT]

FDA approval means vepdegestrant enters clinical practice now. Oncologists prescribing in this setting will need ESR1 mutation testing — via ctDNA or tissue — as a routine companion diagnostic step. Payers will need to establish reimbursement pathways for what will likely be an expensive novel agent. And the PROTAC platform itself is now commercially validated: over 20 PROTACs are in clinical trials for other cancer targets, and this approval sends a signal to the field that the modality works in humans.

[WHAT WE STILL DON'T KNOW]

The magnitude of PFS benefit in VERITAC-2 matters — and the primary trial data should be scrutinized for overall survival data, subgroup performance, and patient-reported outcomes. Whether PROTACs will extend their reach to historically "undruggable" targets like KRAS or MYC — long the holy grail of oncology — remains to be demonstrated in later trials. Access is also an open question: novel targeted therapies at launch are often unavailable in LMICs and to uninsured patients in high-income countries, meaning the populations who bear the highest breast cancer burden may be the last to benefit.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High
• Translation Speed: Already in practice (FDA approval 2026)
• Barrier Analysis: ESR1 testing access (moderate barrier in community settings); cost/reimbursement (significant barrier, especially globally); awareness among community oncologists (solvable through CME and guidelines updates); equity gaps in molecular testing access

[CALL TO ACTION / CLOSING]

The first PROTAC approval is not just a milestone for one drug in one disease — it is proof of concept for a new language of medicine. For patients with ESR1-mutated breast cancer, vepdegestrant is available now. For the rest of oncology, the clock on a new therapeutic era has started.

---

---

[HOOK]

What if the drug you're already taking for diabetes or weight loss was quietly protecting your brain? That is the tantalizing implication of a new large-scale analysis that found people on GLP-1 receptor agonist therapy had 54% lower rates of Alzheimer's disease than comparable patients on other diabetes medicines. The finding is extraordinary — and requires careful handling, because this is observational data, not a randomized trial.

[THE DISCOVERY]

In a study published in Biology Methods and Protocols by Murugadoss, Venkatakrishnan, and Soundararajan, researchers analyzed data from over 29 million patients in a federated electronic health record system. They matched 28,901 adults aged 50 and older who started GLP-1 receptor agonist therapy against 28,901 who started other antidiabetic drugs — carefully balancing them on more than 100 clinical variables using propensity-score matching. The result: GLP-1 RA initiation was associated with a hazard ratio of 0.46 for incident Alzheimer's disease (95% CI 0.29–0.73), meaning roughly half the Alzheimer's risk. The signal held specifically for semaglutide (HR 0.56). All-cause mortality was 54% lower. Heart failure and kidney disease were substantially reduced. Valid negative controls produced null signals, as expected — a methodological strength.

[THE SCIENCE BEHIND IT]

The study uses a "target-trial emulation" framework — a sophisticated approach designed to mimic the conditions of a randomized trial using real-world data. This is not simple data mining; it applies rigorous causal inference methodology and propensity-score matching to minimize confounding. The federated data architecture across multiple health systems, plus semaglutide-specific replication, adds robustness.

But here is where intellectual honesty is essential: this is still observational data. Propensity matching balances measured confounders — but unmeasured ones remain. Patients who receive GLP-1 RAs tend to have better-resourced care, more attentive physicians, and higher baseline health engagement. This "healthy user bias" is one of the most persistent challenges in pharmacoepidemiology and could explain a substantial portion of the observed benefit. Additionally, the authors are affiliated with nference, a health analytics company — a financial conflict worth noting. The authors appropriately call for prospective RCT confirmation.

The main limitation is precisely this: no randomized trial yet exists testing GLP-1 RAs against a control for an Alzheimer's prevention indication in a population not selected for diabetes or obesity.

[WHO THIS HELPS]

The enrolled population — adults 50 and older with at least one documented neuropsychiatric, cognitive, or sensory risk factor — represents a population already at elevated Alzheimer's risk. The vast majority also had T2DM or metabolic comorbidities, which are themselves AD risk factors. If confirmed, the benefit would be most actionable in patients already indicated for GLP-1 therapy on cardiometabolic grounds, where a brain-protective co-benefit would strengthen the prescribing case. The 34% reduction in overall dementia and 54% mortality reduction are additionally compelling.

[THE REAL-WORLD IMPACT]

GLP-1 receptor agonists are already prescribed to tens of millions of people globally. If ongoing randomized trials — several are underway — confirm even a partial version of this signal, it would reshape the prescribing rationale for semaglutide and similar agents beyond metabolic disease into neurological risk reduction. That shift would be one of the most significant expansions of a drug class's indication in modern medicine. For now, this finding is hypothesis-strengthening, not practice-changing for an Alzheimer's prevention indication — but it is among the most scientifically compelling signals in the GLP-1 literature.

[WHAT WE STILL DON'T KNOW]

Whether GLP-1 RAs directly reduce neuroinflammation, amyloid accumulation, or neurodegeneration — or whether the apparent benefit is mediated entirely through cardiometabolic risk reduction (improved blood pressure, weight loss, reduced vascular events) — is unknown. The causal pathway matters enormously for drug development. Prospective RCTs with pre-specified Alzheimer's endpoints are essential, as is independent replication in non-industry-affiliated datasets.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate (strong signal, observational design)
• Translation Speed: 5–10 years (RCTs needed; EVOKE, HEAL, and similar trials ongoing)
• Barrier Analysis: Cost and access to GLP-1 RAs remain major equity barriers; if confirmed for AD prevention, insurance coverage for a new indication would face regulatory hurdles; populations with highest dementia burden (low-income, minority groups) have least access to GLP-1 therapy currently

[CALL TO ACTION / CLOSING]

A 54% reduction in Alzheimer's disease from already-available medicines would be one of the most important medical findings of this century — if true. The trials running now are the ones to watch. Until then, this extraordinary signal is reason for excitement, rigorous skepticism, and urgent investment in definitive prospective evidence.

---

---

[HOOK]

Two of the most successful drugs in medical history are about to get a lot more complicated for prescribers — and in the best possible way. A new mega-analysis of nearly 50,000 patients has revealed that tirzepatide and semaglutide behave in fundamentally different ways when it comes to blood pressure. One cuts hypertension events by 60%. The other keeps blood pressure neutral. And the difference matters today, for patients whose prescriptions are being written right now.

[THE DISCOVERY]

Researchers led by Chen and colleagues in Endocrine pooled data from 32 randomized controlled trials enrolling 47,332 participants with type 2 diabetes or obesity to compare blood pressure-related safety profiles of tirzepatide and semaglutide. The headline findings: tirzepatide significantly reduced hypertension-related treatment-emergent adverse events by 60% (RR=0.40, 95% CI 0.26–0.60, p<0.001) compared to control — making it an exceptionally attractive agent for the many T2DM and obesity patients who also carry a hypertension burden. But tirzepatide also significantly increased hypotension events (RR=2.45, 95% CI 1.35–4.45, p=0.003) in a dose-dependent pattern. Semaglutide, by contrast, showed a neutral blood pressure safety profile — neither markedly raising nor lowering BP-related adverse events.

[THE SCIENCE BEHIND IT]

This is the most rigorous BP-focused analysis for these agents to date. Thirty-two RCTs with nearly 50,000 participants using a random-effects model is as robust as meta-analytic evidence gets in this space. The dose-dependent subgroup analysis of tirzepatide's hypotension signal is particularly important — it means the risk scales with the dose titration pathway, which is clinically actionable (slower titration, more BP monitoring at higher doses). The distinction between tirzepatide's dual GIP/GLP-1 agonism and semaglutide's pure GLP-1 agonism may explain the hemodynamic differences, though the mechanistic pathway is still being characterized.

One important caveat: this meta-analysis pooled trial-reported treatment-emergent adverse events for hypertension and hypotension — categories that may be defined differently across 32 trials with different patient populations, background therapies, and follow-up durations. Access was abstract-only, so full quality assessment of individual trial inclusion criteria requires the primary paper.

[WHO THIS HELPS]

This finding has immediate practical relevance for several clinical phenotypes. Patients with poorly controlled hypertension as a dominant comorbidity may be better served by tirzepatide. Patients with baseline orthostatic hypotension, elderly patients, those on antihypertensives, or frail individuals on polypharmacy face elevated hypotension risk with higher tirzepatide doses — and may be better candidates for semaglutide, which avoids this concern. The finding also has direct relevance to renal patients where blood pressure management is critical, a population frequently evaluated for both agents.

[THE REAL-WORLD IMPACT]

Prescribers can act on this data today. No new regulatory approvals are needed — both drugs are available, and this meta-analysis provides differentiation criteria for individualized drug selection. Endocrinologists, primary care physicians, cardiologists, and nephrologists all have a stake in this finding. Clinical decision support tools and formulary guidance documents should incorporate the tirzepatide hypotension signal, particularly at higher doses. For the tens of millions of patients being initiated on these agents globally, this safety differentiation is among the most immediately translatable findings in this batch.

[WHAT WE STILL DON'T KNOW]

Whether the hypotension risk with tirzepatide translates to clinical outcomes like syncope, falls, or serious cardiovascular events — rather than just reported adverse events — is not established by this meta-analysis. The balance between tirzepatide's hypertension benefit and its hypotension risk in patients with mixed cardiovascular profiles will require more granular individual patient-level data. Long-term BP trajectory data beyond trial periods is also needed.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High (32 RCTs, n=47,332, dose-dependent signal confirmed)
• Translation Speed: Already actionable — 0–1 years for prescribing guidance updates
• Barrier Analysis: Awareness (moderate — needs dissemination to primary care and community endocrinology); cost of both agents remains a major global equity barrier; BP monitoring infrastructure in LMICs may limit harm-reduction capacity for hypotension risk; elderly and frail patients most at hypotension risk are also most likely to be under-monitored in community settings

[CALL TO ACTION / CLOSING]

Tirzepatide and semaglutide are not interchangeable — and now, with the largest BP-focused evidence base ever assembled, we have the data to say exactly why. The right drug for the right patient's blood pressure profile is a prescription decision that clinicians can make more confidently starting today.